Novo Nordisk Sues Hims & Hers Over Ozempic Copycats as the Weight-Loss Drug Wars Escalate
Summary
A recent lawsuit highlights the intensifying conflict between a Danish pharmaceutical company and a telehealth provider, marking a significant development in their ongoing dispute. This legal battle underscores the complexities within the healthcare industry.
Key Insights
What are compounded versions of Ozempic or Wegovy?
Compounded versions are custom-made drugs produced by pharmacies using the active ingredient semaglutide, allowed during shortages for specific patients but not in large batches or for mass marketing after shortages end, as they bypass FDA approval processes.[1][2][3]
Why is Novo Nordisk suing Hims & Hers despite Hims stopping sales of the copycat pill?
Novo Nordisk alleges patent infringement on semaglutide for both Hims' compounded injections mimicking Ozempic and Wegovy, and the recently launched pill, seeking injunctions, damages, and to halt all unapproved compounded sales despite Hims' retreat on the pill.[1][2][4]